pharma · Advanced Malignant Tumors · Metastatic Pancreatic Ductal Adenocarcinoma
Akeso
NovaPharmaNews editorial coverage mentioning Akeso — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2012
- Employees
- 112
- Programs
- 3
- Drugs
- 8
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Akeso — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Akeso — regulatory, clinical, and market analysis.
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
ASCO Preview: Akeso's Ivonescimab Under Scrutiny
As Akeso prepares for a plenary presentation at ASCO 2026, ivonescimab's HARMONi-6 overall survival data will be closely watched. This article covers key takeaways, competitive implications, and next milestones for pharma teams and investors.
ASCO 2026 Preview: Key Data and Trends in Cancer Research
This ASCO preview highlights crucial developments in cancer research, focusing on key data presentations and emerging trends that will shape the oncology landscape. Investors and BD teams should monitor these advancements for strategic insights.
ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study
Structured plan for ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study